CJC-1295 vs CJC-1295 + Ipamorelin Blend
CJC-1295 (GHRH analog (long-acting, with Drug Affinity Complex / DAC)) and CJC-1295 + Ipamorelin Blend (Combination product: GHRH analog (CJC-1295) + GHRP/ghrelin-receptor agonist (ipamorelin)) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | CJC-1295 | CJC-1295 + Ipamorelin Blend |
|---|---|---|
| Compound class | GHRH analog (long-acting, with Drug Affinity Complex / DAC) | Combination product: GHRH analog (CJC-1295) + GHRP/ghrelin-receptor agonist (ipamorelin) |
| Research category | Growth & GH-Axis | Growth & GH-Axis |
| Length (amino acids) | 30 amino acids | Not documented |
| Molecular weight | Approximately 3647 g/mol (with DAC linker) | Not documented |
| Half-life | Substantially extended vs native GHRH; reported on the order of days (approximately 6-8 days) due to albumin binding via DAC | Not documented |
| Origin | CJC-1295 (with DAC) is a synthetic long-acting GHRH analog based on a modified GHRH(1-29) sequence, developed by ConjuChem. It incorporates a Drug Affinity Complex (DAC) that binds serum albumin to greatly extend circulating half-life. | This is not a single molecule but a formulated blend combining CJC-1295 (a GHRH analog) with ipamorelin (a selective ghrelin-receptor GH secretagogue). Blends are commonly prepared in research/compounding contexts to combine two complementary GH-stimulating mechanisms. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How CJC-1295 works
CJC-1295 is a GHRH-receptor agonist that stimulates pulsatile GH secretion from the pituitary. Its GHRH(1-29) backbone carries stabilizing amino-acid substitutions (e.g. at positions 2, 8, 15, 27) that resist DPP-4 degradation, and the DAC group forms a covalent bond with albumin, dramatically prolonging its action. This produces a sustained elevation of GH and IGF-1 rather than sharp discrete pulses.
How CJC-1295 + Ipamorelin Blend works
The blend pairs two distinct mechanisms: CJC-1295 agonizes the GHRH receptor while ipamorelin agonizes the growth-hormone secretagogue (ghrelin) receptor. Because GHRH analogs and GHRPs act on separate pituitary pathways, their combined administration is studied for potentially synergistic, greater-than-additive GH release. Ipamorelin's selectivity is intended to add GH stimulation without notably raising cortisol or prolactin.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
Described in identical terms for both
CJC-1295
CJC-1295 + Ipamorelin Blend
What sets each apart
CJC-1295
The DAC version's albumin binding gives it a far longer half-life (days) than the no-DAC 'Mod GRF 1-29' (minutes), making it the long-acting member of the CJC-1295 family.
CJC-1295 + Ipamorelin Blend
Unlike single-agent GHRH analogs or GHRPs, this is a combination formulation designed to engage both the GHRH and ghrelin receptor pathways simultaneously.
Documented together as a research blend
Cross-referenced for research context — not a usage or combination recommendation.
Frequently asked questions
What is CJC-1295 (with DAC)?
CJC-1295 is a synthetic long-acting analog of GHRH(1-29). This slug refers to the DAC (Drug Affinity Complex) version, which carries a maleimidopropionic acid linker that covalently binds serum albumin after injection, dramatically extending its circulating half-life to several days.
What is the difference between CJC-1295 with DAC and without DAC?
Both share the same modified 29-amino-acid GHRH core with substitutions that resist DPP-IV cleavage. The DAC version adds an albumin-binding complex giving a half-life of roughly 6-8 days, producing a sustained 'GH bleed,' whereas the no-DAC version (Mod GRF 1-29) has only a ~30 minute half-life and produces discrete pulses.
What does the long half-life mean for research design?
Because CJC-1295 with DAC persists for days, it raises the baseline of GHRH tone rather than producing sharp pulses. In research this is described as elevating overall GH and IGF-1 output; studies often examine how this sustained tone interacts with pulsatile GHRP stimulation.
What is the CJC-1295 / Ipamorelin blend?
This is a combination research preparation containing both CJC-1295 (a GHRH analog) and ipamorelin (a selective GHRP / ghrelin-receptor agonist) in a single vial. It formalizes the most widely referenced GH-secretagogue research pairing into one product.
Why are CJC-1295 and ipamorelin combined?
The two act on different receptors: CJC-1295 on the GHRH receptor and ipamorelin on the ghrelin receptor (GHS-R1a). Stimulating both pathways simultaneously produces a synergistic GH pulse larger than either compound alone, which is the rationale for the blend in research settings.
Does the blend use CJC-1295 with DAC or without DAC?
Blends vary by source. Many CJC-1295 + ipamorelin blends use the no-DAC (Mod GRF 1-29) form so that both components are short-acting and produce a clean pulsatile profile, but some use the DAC version for sustained GHRH tone. The specific form should be confirmed on the product's COA.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.